Open AccessMagnificamide is a new effective mammalian a-amylase inhibitor
Author(s) -
Oksana Sintsova,
Elena Leychenko,
Elena Leychenko,
A. P. Kalinovskii,
Margarita Monastyrnaya,
É. P. Kozlovskaya
Publication year - 2019
Publication title -
doklady akademii nauk. rossijskaâ akademiâ nauk
Language(s) - English
Resource type - Journals
ISSN - 0869-5652
DOI - 10.31857/s0869-56524894429-432
Subject(s) - acarbose , amylase , recombinant dna , drug , anemone , chemistry , type 2 diabetes mellitus , pharmacology , diabetes mellitus , biochemistry , enzyme , medicine , endocrinology , biology , gene , botany
Recombinant analog of sea anemone Heteractis magnifica peptide was obtained and kinetic parameters of its interaction with mammalian -amylases were determined. Magnificamide inhibits -amylases significantly stronger than a medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.